Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS 2 articles
May 4, 2009
- Takeda Deals with Soaring R&D Costs through 2 Strategies
May 4, 2009
- Sanofi-aventis Aims at No. 5 Place in Japan in 5 Years: Dr Chocat
May 4, 2009
- Enhance Japan's Presence in Multinational Clinical Trials
May 4, 2009
- Market for Drugs for Hyperlipidemia to Exceed ¥400 Bil. in 2013: Fuji-Keizai Data Book
May 4, 2009
- NEDO to Start Large-Scale Clinical Trial on AD
May 4, 2009
- Shionogi to Develop In-house Products by Sugar Chain Analysis, Molecular Imaging
May 4, 2009
- Large-Scale Trial on Risk of Bone Fractures due to TZD Underway in Europe
May 4, 2009
- Gov't to Earmark ¥79.0 Bil. to Promote Development of Unapproved Drugs
May 4, 2009
- Santen Licenses Tapros to Merck
April 27, 2009
- Shire to Independently Commercialize "Ultra" Orphan Drugs in Japan
April 27, 2009
- Janssen Enters 2nd Growth Phase in 2009
April 27, 2009
- Combined Deficits for Health Insurance Societies Remain at Record-High Level
April 27, 2009
- MEDICAL DEVICE NEWS IN BRIEF
April 27, 2009
- No Progress on Discussions on Online Sales of OTC Drugs
April 27, 2009
- Taiyo Acquires Schering-Plough's Kasukabe Plant
April 27, 2009
- Korosho Proposes New Policy for Approval of Generics of Drugs Covered by Valid Use Patents
April 27, 2009
- R&D NEWS IN BRIEF
April 27, 2009
- CoreMed Expands Drug Development Support Services in Europe
April 27, 2009
- Potential Biomarker for Oxaliplatin Discovered: Prof. Tanigawara
April 27, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…